February 14, 2025 10:26 Author: Chen Xi Source: Shanghai Securities Journal · China Securities Network

On the evening of February 13th, Beilu Pharmaceutical announced that it had successfully received the Drug Registration Certificate for Compound Polyethylene Glycol Electrolyte Powder (III) approved and issued by the National Medical Products Administration. This drug belongs to Class 4 of chemical drugs and is considered to have passed the quality and efficacy consistency evaluation of generic drugs.

Compound polyethylene glycol electrolyte powder, as a commonly used intestinal cleansing and penetrating laxative in clinical practice, has a broad market demand. According to data from MineNet, in 2023, its terminal sales in public medical institutions in China exceeded 1.3 billion yuan, and compound polyethylene glycol electrolyte powder (III) has been included in the tenth batch of national centralized drug procurement. This approval further enriches the product pipeline of Beilu Pharmaceutical in the field of digestive system diseases and enhances its market competitiveness.

Beilu Pharmaceutical continues to make efforts in drug research and innovation, constantly expanding its product line. How to make breakthroughs in the market with new products in the future is worth paying attention to. (Chen Xi)